Crossmark

MRI-based evaluation for predicting pathological response and monitoring reactive angioma evolution in triple-negative breast cancer undergoing neoadjuvant chemoimmunotherapy

Crossref DOI link: https://doi.org/10.1186/s40644-025-00980-z

Published Online: 2025-12-29

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Lin, Luyi

Zheng, Jinlong

Yang, Fan

Zuo, Ke

Zhou, Jiayin

Su, Guanhua

Ma, Xiaowen

You, Chao

Gu, Yajia
Funding

Funding for this research was provided by:

Shanghai Municipal Health Commission General Project (202240241)

Special Research Fund for Clinical Studies of Innovative Drugs after Market Launch (WKZX2024CX103301)
License Information

Text and Data Mining valid from 2025-12-29

Version of Record valid from 2026-01-30
More Information

Article History

Received: 8 June 2025

Accepted: 17 December 2025

First Online: 29 December 2025

Declarations

:

: The study was approved by the Ethics Committee of the Institutional Review Board (IRB) of our institution. All patients provided written informed consent before enrollment.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below